Aeonvital closes Series Pre-A round to advance TIL therapy and HPV vaccine; Huixinyigu, Junshi, Everest, BeiGene, Luye
Elise Mak · 06/10/2022
Aeonvital, of Beijing, has closed a Series Pre-A financing round to advance human trials of its tumor-infiltrating lymphocyte (TIL) therapy candidate and preclinical trials of its therapeutic HPV vaccine. More news from Huixinyigu, Junshi, Everest, BeiGene, BI, Lilly, Luye.
READ MORE
Canwell nabs $31M in Series A to advance TLR7 agonist; Novastage, Bayer, Everest - News of the day
Elise Mak · 03/18/2022
Guangzhou biotech Canwell closed a Series A round of RMB200 million ($31.4 million) to advance CAN1012, a TLR7 agonist, in multiple tumor types. More news from Novastage, Bayer, Everest.
READ MORE
Everest gains global rights to oral COVID-19 drugs; REC Bio - News of the day
Elise Mak · 01/14/2022
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
READ MORE
Chinook sets up China joint venture SanReno to tackle kidney diseases; BeyondSpring, Everest, Zai Lab - News of the day
Elise Mak · 12/02/2021
Kidney disease biotech Chinook Therapeutics has set up a joint venture called SanReno Therapeutics with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners Chinam, and more news from BeyondSpring, Everest, Zai Lab and ITabMed.
READ MORE
Everest partners with AbCellera to gain antibodies for up to 10 targets
Sarina Yang · 09/24/2021
​Everest Medicines and AbCellera entered a multi-year collaboration to discover therapeutic antibodies for up to 10 targets selected by Everest. This is the third deal Everest disclosed in two weeks.
READ MORE
After mRNA, Everest gains BTK inhibitor in $561M deal to fight renal diseases
Elise Mak · 09/17/2021
Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million.
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement